Vaxxinity

Vaxxinity company information, Employees & Contact Information

Explore related pages

Related company profiles:

Vaxxinity is a U.S.-based global biotechnology company pioneering a new class of medicines to democratize health. Headquartered in Dallas, TX, with operations in the United States, Latin America, Europe and Asia, the company’s proprietary technology platform has enabled the innovation of synthetic peptide vaccines designed to prevent or treat infectious diseases, including COVID-19, and chronic diseases, including Alzheimer's, Parkinson’s, migraine, and hypercholesterolemia.. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health. The key to the platform is the proprietary library of UBITh peptides, which are immunosilent, avoiding inflammation, and when linked to custom-designed target antigens, can elicit highly specific antibodies.

Company Details

Employees
22
Address
505 Odyssey Way, Exploration Park, Cape Canaveral,florida 32953,united States
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Culver City.
HQ
Cape Canaveral, Florida
Looking for a particular Vaxxinity employee's phone or email?

Vaxxinity Questions

News

Vaxxinity Issues Shareholder Letter - GlobeNewswire

Vaxxinity Issues Shareholder Letter GlobeNewswire

Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech

Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market Fierce Biotech

CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants - CEPI

CEPI to co-fund Vaxxinity's pivotal Phase 3 UB-612 heterologous booster trial to combat SARS-CoV-2 variants CEPI

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - Yahoo Finance

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates Yahoo Finance

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease - Florida Hospital News and Healthcare Report

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease Florida Hospital News and Healthcare Report

Vaxxinity’s Immunotherapy Meets Phase I Goals in Parkinson’s Patients - Inside Precision Medicine

Vaxxinity’s Immunotherapy Meets Phase I Goals in Parkinson’s Patients Inside Precision Medicine

Vaxxinity’s Phase III Covid-19 booster trial meets endpoints - Clinical Trials Arena

Vaxxinity’s Phase III Covid-19 booster trial meets endpoints Clinical Trials Arena

Vaxxinity Signs Purchase Order with the Government of Paraguay for 1 Million Doses of Vaxxinity’s UB-612 COVID-19 Vaccine - Business Wire

Vaxxinity Signs Purchase Order with the Government of Paraguay for 1 Million Doses of Vaxxinity’s UB-612 COVID-19 Vaccine Business Wire

Vaxxinity making vaccines to change the world - Labiotech.eu

Vaxxinity making vaccines to change the world Labiotech.eu

Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial - Nature

Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial Nature

Dallas District Court Split in High-Stakes Stock Dispute - Inforney News

Dallas District Court Split in High-Stakes Stock Dispute Inforney News

Clinical Trial of Investigational Vaccine to Treat LDL Cholesterol Underway - Diagnostic and Interventional Cardiology

Clinical Trial of Investigational Vaccine to Treat LDL Cholesterol Underway Diagnostic and Interventional Cardiology

Mixed fortunes for the neurodegeneration therapy pipeline in 2024 - drugdiscoverytrends.com

Mixed fortunes for the neurodegeneration therapy pipeline in 2024 drugdiscoverytrends.com

Details Behind Potential Phase 2 Trial With UB-312 Alpha Synuclein Vaccine for Parkinson Disease - NeurologyLive

Details Behind Potential Phase 2 Trial With UB-312 Alpha Synuclein Vaccine for Parkinson Disease NeurologyLive

Vaxxinity CEO Mei Mei Hu on vaccine research and democratising health - Pharmaceutical Technology

Vaxxinity CEO Mei Mei Hu on vaccine research and democratising health Pharmaceutical Technology

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock - Yahoo Finance

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock Yahoo Finance

Vaxxinity concludes subject enrolment in Phase III Covid-19 vaccine trial - Clinical Trials Arena

Vaxxinity concludes subject enrolment in Phase III Covid-19 vaccine trial Clinical Trials Arena

Vaxxinity, University of Central Florida launch collaboration to advance medicines for use in space - Fierce Biotech

Vaxxinity, University of Central Florida launch collaboration to advance medicines for use in space Fierce Biotech

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024 - Yahoo Finance

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024 Yahoo Finance

Help wanted: Vaxxinity seeks a partner to press ahead with Alzheimer's treatment - Fierce Biotech

Help wanted: Vaxxinity seeks a partner to press ahead with Alzheimer's treatment Fierce Biotech

Vaccines show promise against common chronic diseases - Gavi, the Vaccine Alliance

Vaccines show promise against common chronic diseases Gavi, the Vaccine Alliance

A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2 - Taylor & Francis Online

A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2 Taylor & Francis Online

Vaxxinity, University of Florida join for work on Parkinson’s vaccine - Parkinson's News Today

Vaxxinity, University of Florida join for work on Parkinson’s vaccine Parkinson's News Today

Vaxxinity is brewing up meds for a spacefaring future - Pharma Voice

Vaxxinity is brewing up meds for a spacefaring future Pharma Voice

Migraine Vaccine Shows Comparable Efficacy to Monoclonal Antibodies for Migraine Relief: Jean-Cosme Dodart, PhD - NeurologyLive

Migraine Vaccine Shows Comparable Efficacy to Monoclonal Antibodies for Migraine Relief: Jean-Cosme Dodart, PhD NeurologyLive

A Potential Parkinson’s Treatment Has Promising Results - Time Magazine

A Potential Parkinson’s Treatment Has Promising Results Time Magazine

UB-312 Reduces α-Synuclein in Parkinson Disease in Phase 1 Trial - NeurologyLive

UB-312 Reduces α-Synuclein in Parkinson Disease in Phase 1 Trial NeurologyLive

Vaxxinity Has a Rough Public Debut - Nasdaq

Vaxxinity Has a Rough Public Debut Nasdaq

Dallas-Based Vaxxinity Prepares for $100M IPO; Aims to Turn Immune Systems Into 'Antibody Factories' - Dallas Innovates

Dallas-Based Vaxxinity Prepares for $100M IPO; Aims to Turn Immune Systems Into 'Antibody Factories' Dallas Innovates

Woman of the Week: Vaxxinity’s Mei Mei Hu - Pharma Voice

Woman of the Week: Vaxxinity’s Mei Mei Hu Pharma Voice

VAXX IPO News - Vaccine biotech Vaxxinity sets terms for $101 million IPO - renaissancecapital.com

VAXX IPO News - Vaccine biotech Vaxxinity sets terms for $101 million IPO renaissancecapital.com

Vaxxinity (VAXX) Stock Price, News & Analysis - MarketBeat

Vaxxinity (VAXX) Stock Price, News & Analysis MarketBeat

Dallas-based Vaxxinity begins Phase 3 trial for COVID-19 booster vaccine - Dallas News

Dallas-based Vaxxinity begins Phase 3 trial for COVID-19 booster vaccine Dallas News

Why Is Vaxxinity (VAXX) Stock Down 58% Today? - InvestorPlace

Why Is Vaxxinity (VAXX) Stock Down 58% Today? InvestorPlace

Vaxxinity publishes positive results in Alzheimer’s trial - Longevity.Technology

Vaxxinity publishes positive results in Alzheimer’s trial Longevity.Technology

Fast-Tracked Alzheimer’s Vaccine Seems to Work, But Phase 3 Trials Stalled - Being Patient

Fast-Tracked Alzheimer’s Vaccine Seems to Work, But Phase 3 Trials Stalled Being Patient

Top Vaxxinity Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant